Please login to the form below

Not currently logged in
Email:
Password:

Roche's haemophilia A drug hits targets in registration trial

Emicizumab from Japanese affiliate Chugai cleared a phase III trial

Roche Basel Switzerland 

Roche's bid to enter the multibillion-dollar market for haemophilia drugs has moved closer, after its lead candidate for haemophilia A cleared a phase III trial.

Emicizumab (ACE910) - discovered by Roche's Japanese affiliate Chugai - is a double-headed (bispecific) antibody targeting clotting factors IXa and X and mimics the function of factor VIII, the usual treatment for haemophilia A. 

Emicizumab is being positioned initially as another treatment option for haemophilia A patients who develop a type of antibody (inhibitor) that attacks their factor VII drug, reducing its ability to stop blood clots. Inhibitor development is currently the most significant treatment complication seen in patients with haemophilia, estimated to occur in 5% to 13% of patients, depending on the severity of their disease.

The HAVEN 1 showed prophylactic dosing of emicizumab achieved a statistically significant reduction in the number of bleeds over time compared to no prophylaxis in haemophilia A patients aged over 12 with inhibitors. Roche says it intends to discuss the data with regulatory authorities in 2017 with a view to filing for marketing approval.

"Since the mid-1990s, there have been incremental improvements in the treatment of haemophilia A with inhibitors,” said Alain Baumann, chief executive of the World Federation of Haemophilia (WFH). 

"The current burden of treatment is significant [and] filling this need would be a significant advance in our quest to achieve 'Treatment for All', including those living with inhibitors."

Analysts at Credit Suisse have suggested that sales of emicizumab could be $600m in 2020 for haemophilia A patients with inhibitors, rising to $1bn if Roche and Chugai can also gain approval for non-inhibitor patients. 

If approved, emicizumab will break into a market split between Shire (Baxalta), Bayer, Novo Nordisk, Pfizer and CSL Behring for many years. 

Biogen joined the pack in 2014 with the launch of longer-acting therapies for haemophilia A and B - also tipped as potential blockbusters - and the established players are also rolling out improved and longer acting products.

Article by
Phil Taylor

23rd December 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics